Relay Therapeutics, Inc. (RLAY) stock
RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.09+0.01 (+0.06%)
Close on Nov 13, 2026Market cap $3.96BP/E –Yield –
Relay Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Relay Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -2837.0%. For fiscal 2025 it was -1800.6%, against -3374.7% the year before. The highest annual figure on record is -63.4% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1800.6% | +1574.1 |
| FY2024 | Dec 31, 2024 | -3374.7% | −2036.1 |
| FY2023 | Dec 31, 2023 | -1338.7% | +19697.5 |
| FY2022 | Dec 31, 2022 | -21036.1% | −9023.2 |
| FY2021 | Dec 31, 2021 | -12012.9% | −11949.5 |
| FY2020 | Dec 31, 2020 | -63.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -23916.3% | −22912.7 |
| Q1 FY2026 | Mar 31, 2026 | -2443.0% | −1629.7 |
| Q4 FY2025 | Dec 31, 2025 | -784.1% | −523.3 |
| Q2 FY2025 | Jun 30, 2025 | -10395.1% | +72382.2 |
| Q1 FY2025 | Mar 31, 2025 | -1003.6% | +40695.1 |
| Q1 FY2024 | Mar 31, 2024 | -813.3% | +25867.7 |
| Q3 FY2023 | Sep 30, 2023 | -260.8% | +24207.8 |
| Q2 FY2023 | Jun 30, 2023 | -82777.3% | −61739.5 |
| Q1 FY2023 | Mar 31, 2023 | -41698.7% | −26890.6 |
| Q4 FY2022 | Dec 31, 2022 | -26681.0% | −14784.0 |
| Q3 FY2022 | Sep 30, 2022 | -24468.6% | −15334.5 |
| Q2 FY2022 | Jun 30, 2022 | -21037.8% | +1876.8 |
| Q1 FY2022 | Mar 31, 2022 | -14808.1% | −10377.0 |
| Q4 FY2021 | Dec 31, 2021 | -11897.0% | – |
| Q3 FY2021 | Sep 30, 2021 | -9134.1% | – |
| Q2 FY2021 | Jun 30, 2021 | -22914.6% | – |
| Q1 FY2021 | Mar 31, 2021 | -4431.1% | – |
See a number that looks wrong?